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Abstract
The goal of this work was to investigate the sources of stigma not only from primary
literature, but also using a survey conducted at the university of Tennessee-Knoxville. The
survey also sought to correlate awareness of HIV progression, transmission, and treatment to
level of stigma. Though there was no overall correlation, the survey did find that fear of
transmission correlated significantly with overall stigma. The results of the survey aligned with
other studies performed. The paper goes on to elucidate the way stigma affects people living with
HIV and their access to medical care, and provides a current outlook on if and how society can
create a more constructive environment for people living with HIV.

Introduction
Human immunodeficiency virus (HIV) has been a hot research topic since its debut in the
1980s. The retrovirus is excellent at what it does, which is attack the immune cells of its
unfortunate host so that it can run rampant in the body. Though it has been a prevalent disease
for over thirty years, the best way of treating HIV remains combined oral antiretroviral
treatments, which seek to disable viral machinery in a multitude of ways. Current research on
creating vaccines and cures has told us much about the disease itself, but has not yielded safe
ways to eradicate the virus. The most common conclusion in HIV research is that the virus is
more complicated than previously thought. Despite failed attempts at truly novel ways of treating
HIV, improvements to familiar treatments have been made. But treating HIV is not the only
challenge surrounding those afflicted. Ever since it reached the public eye, it has been one of the
most stigmatized diseases of modern times.
To truly understand current social interaction with people living with HIV (PLHIV), we
must also understand the history of how HIV came to the forefront as a stigmatized disease. It
has been established that the virus was transferred to humans in the 1920s or earlier through a
variant of simian immunodeficiency virus (SIV), most likely due to the consumption of monkey
in the Kinshasa. By the 1960s, HIV had made its way to Haiti (Faria 2014). When hospitals in
North America saw the first few cases of HIV in the 80s, they had no way of knowing what they
were dealing with. They only knew it presented with Kaposi’s sarcoma (KS) and abnormal lung
infections, and that both were signs of an underlying immune problem. A host of papers
published by the Centers for Disease Control and Prevention (CDC) in the early 80s showed ever
increasing symptoms of immunodeficiency in homosexual men, intravenous drug users, and
blood transfusion recipients. The disease took on many names, such as “gay cancer,” “gay

compromise syndrome,” and today’s “acquired immunodeficiency syndrome”(Brennan 1981,
Auerbach 1984, McKay 2014). A 1984 study in the American Journal of Medicine became the
first of many mapping the spread of HIV based on KS and opportunistic infection in homosexual
males, concluding that a certain “patient O” had been the source of HIV/AIDS transmission in
New York, Los Angeles, and San Francisco, among others (Auerbach 1984). Patient zero, as it
came to be called, was eventually uncovered as Gaetan Dugas, a homosexual Canadian flight
attendant who was in prime position to carry a sexually transmitted virus from coast to coast
(Shilts 1987). His symptoms began in 1980, and his continued sexual forays ensured
transmission across the United States. According to journalist and novelist Randy Shilts, Dugas
was intent on living a full life despite of his malaise, and despite the consistent warnings from his
doctors. Two years after his death, his story was published as a part of Shilts’s interpretation of
the HIV phenomenon, And the Band Played On. The “Patient Zero” story gained enough
attention to be on 60 Minutes and other news headlines, bolstering the American public’s
understanding of Dugas and the gay community as the villains behind HIV/AIDS. However,
Robert McKay opposes this depiction of Dugas in his 2009 article addressing the shortcomings
of Shilts’s rendition. Shilts used edited interviews to present Dugas as a self-loathing character
so filled with anger at himself and his condition that he intentionally infected other gay men. At
the very least, Shilts writes, he was so recklessly intent on carrying out his lifestyle that the
collateral damage was of little consequence. But, as McKay points out, the CDC only confirmed
HIV/AIDS as a sexually transmitted virus in April of 1984, one month after Dugas’s death
(Administration 2014, McKay 2014). Thus, some see Dugas as the antagonist of the HIV/AIDS
saga, while others count him as an unfortunate victim of a novel virus whose story happened to

be the most publicized. Whatever the case, Randy Shilts’s book was just part of the highly
stigmatizing media coverage when HIV/AIDS first became a problem in North America.
Around the same time Dugas was showing his first symptoms of HIV, the new disease
was reported to the CDC. However, it was three years before researchers understood the disease
as a sexually-transmitted virus, and six before the first approved treatment was available.
Fortunately, the Food and Drug Administration (FDA) had established a faster protocol to get
treatments approved, started testing blood and plasma stocks, was approving better ways of
testing for HIV, and approved Retrovir as the first HIV/AIDS treatment by 1987 (Administration
2014). Despite progress, President Reagan’s response is still criticized today as being too little
too late. It was not until 1985 that he addressed HIV as an issue, and even then he failed to
acknowledge that high-risk groups existed outside of the gay community and intravenous drug
users (Richert 2009).
Between media coverage and inadequate government reaction, PLHIV were destined for a
stigmatized existence. The immediate reaction of the U.S. government—silence—represents the
most dangerous aspect of living with HIV. Worldwide, silence is all too often the primary way
PLHIV cope with stigma. As one HIV-negative man said of his HIV-positive wife, “I was
actually safe because I knew her status” (Rispel 2015). Knowledge and disclosure are the keys to
coexistence with diseases like HIV/AIDS. Not only do these help PLHIV be more comfortable in
society, but also allow others to better understand the needs that come with living with HIV. In
this dissertation, the possible connections between awareness of HIV and stigmatizing HIV will
be explored. How might social stigma borne out of ignorance affect the inclination and ability of
PLHIV to obtain the necessary resources to manage HIV? And can researchers do more to help
PLHIV access treatment and live more enjoyable lives?

Pathogenesis
What makes HIV such a formidable virus? As a retrovirus, HIV contains two copies of
single stranded RNA. Upon entering its host, it seeks out CD4+ cells, which include
macrophages, dendritic cells, and CD4+ T-cells. After gaining access to these cells, viral reverse
transcriptase can copy the viral ssRNA and convert it to double stranded DNA. The viral DNA
then enters the host cell’s nucleus and integrates itself into the host genome. This aspect of HIV
enables it to remain latent for months, even years, before becoming an active virus. Once
activated, the integrated viral DNA is transcribed into RNA, which is packaged in viral proteins
produced using the cell’s machinery. From there, new viruses can be released from the host cells
to continue the viral life cycle (MacPherson 2012). When someone with HIV has a high level of
viral RNA in his or her blood, he or she is increasingly the subject of opportunistic infection.
Once that person has a CD4+ count below 200 cells/mm, an HIV infection becomes a case of
AIDS (CDC 2015). Current treatments are able to rid the body of actively infected cells so that
the virus is undetectable, but HIV’s ability to integrate complicates completely eradicating the
virus. Because latent cells can survive for long periods of time, they are a constant source of the
virus. Since the virus is not active in these cells and established treatments are unable to target
the machinery that has not been transcribed, it has so far been impossible to truly cure PLHIV in
all individuals. Even outside of latency, HIV can be highly variable, giving way to resistant
strains and faster progression of the disease (Acheson 2007). Transmission of the virus is most
commonly through sex and blood contact, particularly through needle sharing. HIV can also be
passed through contaminated needle sticks and blood transfusions, or from mother to child
during childbirth. Contrary to the popular misconception, HIV is not passed through saliva or
insect vectors, such as mosquitoes (CDC 2015). Transmission is best prevented through

practicing safe sex and not sharing needles. Adherence to HIV treatments and/or pre-prophylaxis
treatments (PrEP) also greatly reduces risk of transmission by either keeping the virus at an
undetectable level or preventing initial infection of the virus. If someone has a high level of
sexual activity, getting tested annually is recommended (Administration 2014).

Treatments
One of today’s great challenges of medical research is the ongoing struggle to develop
the most effective treatments to HIV with the least toxicity and lowest cost. The most common
treatment regimens include three different classes of antiretroviral medications . Because HIV is
notorious for its rapid mutation, these drugs are used together in a cocktail to avoid a resistant
viral strain slipping through the cracks. Using a combination of medications as a way of
managing HIV is called cART (combined antiretroviral therapy) or HAART (highly active
antiretroviral therapy) (Prevention 2016).
In the three decades since HIV first surfaced, prevalent treatment options have branched
out from the FDA’s first treatment approval AZT (azidothymidine) in 1987. Classified as a
nucleotide reverse transcriptase inhibitor (NRTI), AZT targets an HIV-specific enzyme called
reverse transcriptase. If the function of the reverse transcriptase can be disrupted, the RNA
genome contained within the viral capsid cannot be converted to DNA that can be inserted into
the host cell’s genome. Thus, AZT remains the reference point for most treatments developed .
More than half of the available treatments for HIV target reverse transcriptase. Though having so
many versions of medications with similar function may seem redundant, the variety allows
better treatment plan personalization and higher accessibility. However, using NRTIs alone has
proven to be insufficient in cases of viral resistance. The drugs also have a high toxicity and

therefore several unpleasant side effects (Este 2010). One of the most recent NRTI successes is
the drug Truvada. It is approved for preexposure prophylaxis, meaning it can prevent HIV from
truly infecting cells. This has been received as an opportunity for HIV-discordant couples and
others in high risk groups to greatly reduce their risk of transmission (Prevention 2014).
Non-nucleotide reverse transcriptase inhibitors (NNRTIs) also target reverse
transcriptase, but have a different mode of attack. Instead of competing with nucleotide
substrates that would normally bind to reverse transcriptase as NRTIs do, it attaches to another
binding site to change to render the active site useless, completely block any kind of binding.
These have shown fewer side effects due to less interference with host DNA transcription
machinery (De Clercq 1998).
To ameliorate the issues of side effects and resistance, protease inhibitors (PIs) have been
developed to target a different area of the HIV life cycle. Rather than inhibiting genome
replication, the viral proteins made as a result of HIV’s successful genome replication are kept
from being properly cleaved into fully functional proteins by viral proteases. Though not usually
prescribed as a sole form of treatment, PIs have been shown to be more efficient in controlling
viral load. While protease inhibitors can lead to viral resistance, the phenomenon is observed less
often than in NRTIs (Paredes 2010).In addition, PIs are not as effective in crossing the bloodbrain barrier and thus leave room for improvement (Ghosh 2006). Because PIs are effective but
fall short in reaching as many tissues as NRTIs/NNRTIs, this class of drug is generally used as
one of three different drugs in cART (Prevention 2016).
One of the most recent developments in cART options is the fusion inhibitor. This
particular drug takes advantage of the fact that, like most viruses, HIV must bind to specific
receptors on the outside of its targeted immune cells to enter the cell and hijack its machinery.

By blocking the receptors HIV uses to gain entry, fusion inhibitors prevent the virus from ever
entering the target cell. With only one fusion inhibitor currently on the market, these types of
medications are still largely experimental, but are expected to be highly effective for individuals
with unusually resistant HIV strains. The approach fusion inhibitors take to HIV—a ligand and
receptor interaction—is favored to lead the field in coming years (Fumakia 2016).
Finally, integrase inhibitors (INIs) are another new addition to HIV treatments present a
new way of attack. These prevent viral DNA from being inserted into the host genome, thereby
disabling the virus’s ability to create viral proteins and progeny. INIs have a higher efficacy as
well as a less prevalent association with viral resistance than NRTIs or PIs. These qualities make
them prime for people infected with more resistant strains of HIV (Andreoni 2015).
However, these medications only tell half of the story. They serve as the first stepping
stones to achieving a functional cure, which serves to keep the virus at undetectable levels in the
blood without prolonged medication, thereby almost eliminating the transmission risk and
symptoms of HIVwithout relying on adherence to medication. This strategy is a long term
treatment which keeps new cells from becoming infected with extant viruses and allowing the
reservoir to shrink, but not be completely eliminated. Though the current therapies discussed
thus far can accomplish these undetectable levels of HIV, the therapy is lifelong and quite costly,
which motivates the research for such a “cure”. The second, more idealistic approach in research
is complete eradication of the virus from individuals, called a sterilizing cure. While the idea of a
“total cure” is attractive, the instances in which viruses have been completely removed from the
body are marginal at best. Simply put, it is not reasonable to expect a single treatment to be
effective for such a virus.

Several avenues for total cures have been explored, focusing on both host and viral
mechanisms. Gene editing is the basis for many recent attempts because it offers an opportunity
to not only rid the host’s genome of HIV-derived DNA, but also render the host cell completely
impermeable to the virus. Removing integrated viral DNA is generally accomplished by using a
known DNA sequence to create a target for an enzyme to cleave out. The same idea can apply to
editing the cell before it is ever infected. If the DNA coding for the receptors HIV uses to gain
access to the cell can be removed, the receptors themselves will never be there for HIV to use.
Though this option would present a long term or even permanent treatment, actually targeting the
correct genes without removing other important parts of the host genome has proved difficult
(Bobbin 2015).
After cell entry and genomic integration, the next logical mechanism to target is RNA
synthesis and processing. Ribozymes, or RNA sequences acting as enzymes, can seek out and
destroy mRNA created as a result of HIV integrating into the host genome. A similar option
known as RNA interference uses small interfering RNA (siRNA) to target viral RNA sequences
(Bobbin 2015). These naturally occurring siRNAs act to silence mRNA so that the protein it
codes for never comes to fruition. Though siRNA is used in preexisting host mechanisms, siRNA
can be synthesized to target HIV-related mRNA (Carthew 2009). Another tactic is to create socalled RNA decoys and RNA aptamers. These bind and therefore debilitate the viral proteins by
acting as inhibitors. While RNA-based approaches are safer than gene editing and are closer to
being available to the public, the drawback is that most developed treatments are short term
(Bobbin 2015).

Current Prevalence of Stigma
Because so little was known about HIV in the eighties, stigma closely followed the fear
brought on by the mysterious disease. However, PLHIV have yet to escape a stigma created
decades ago. In a 2015 study on avoidance of PLHIV at a university in the Netherlands, subjects
were placed in a virtual reality setting in a hospital and were told to memorize chart information
for patients afflicted with HIV, cancer, or a broken limb. Behavior around each type of patient
was gauged based on interpersonal space, speed of approaching and leaving patients, and head
orientation. The virtual patients also varied between homosexual and heterosexual. The study
found that HIV-positive males were more frequently subjected to avoidance and stigmatizing
behaviors, such as being kept at farther distances, being stared at more, and having people walk
away faster than HIV-negative individuals. These behaviors were even more prevalent toward
homosexual men diagnosed with either cancer or HIV, indicating a generalized stigma toward
diagnosed homosexual men (Toppenberg 2015).
Though having these types of studies is useful and necessary, it does not take looking at
recent peer-reviewed articles to see PLHIV and high risk groups being stigmatized. The most
recent celebrity to publicly announce a positive serostatus is Charlie Sheen. That he had HIV was
news in itself, but the fallout of his announcement was incredible. There was hardly a news
source who did not report about Charlie Sheen’s “former porn star girlfriend” being uninformed
of his status (Etkin 2015). Why was it worth mentioning that his ex-partner was a sex worker
before all of the information was available? Was it a covert way of saying he should have seen it
coming? Other headlines surrounding HIV at the time may not stigmatize HIV directly, but have
inaccurate information that could promote a flawed understanding of HIV and AIDS. Perhaps the
worst offender was the ENQUIRER in its article about an unnamed celebrity’s “struggle with

AIDS,” when the writer was actually referring to a recent positive HIV status. The magazine
asserted that “decades of debauchery [had] finally caught up with [the celebrity]” (Jessica 2015).
Another article from ENQUIRER named celebrity Danny Pintauro as being HIV positive, but
called him “AIDS-stricken” instead (Anonymous 2015). These headlines spread misinformation,
the stigma already surrounding HIV, and decreased willingness for PLHIV to disclose their
status and get proper help (Sayles 2007). Another point of stigmatization has been the fairly
recent arrival of the PReP drug Truvada, which has been celebrated as a promising way to
prevent transmission in higher risk demographics. Despite this immensely positive news, some
high profile people in the LBGT community were quick to point out the promiscuity such a drug
might allow (Calabrese 2015). Zachary Quinto commented, “…these drugs are not to be taken to
increase our ability to have recreational sex”(Berlin 2014). While he is not wrong that some may
see having a “magic pill” should allow just that, he ignores the huge benefit for people,
promiscuous and nonpromiscuous alike, in being able to have sex with others without the
constant anxiety of possibly transmitting HIV (Calabrese 2015).
However, stigma in HIV extends well beyond the United States and western Europe. In a
2010 study by Turan, et al., it was noted that pregnant women in Kenya are less likely to get
tested for HIV, keep up with antenatal prevention of HIV transmission, and seek help from
maternity services when facing perceived stigma of HIV from their families and the community.
Pregnant women are often the first members of their families tested for HIV, and in the event of
a positive screening, can be seen as introducing the virus to their families. The study was able to
confirm that a major predictor of HIV test acceptance was anticipated male partner approval or
disapproval (Turan 2010). These results are important because PLHIV need to feel comfortable

in seeking knowledge and help for their condition to prevent further spread of HIV, particularly
in mother-to-child scenarios and in areas that have high transmission rates.

A Survey of Stigma at UTK
Based on these reports, a survey inquiring about both HIV awareness and stigma was
performed across the University of Tennessee-Knoxville student and faculty population.
Respondents were recruited through email and social media, and were kept completely
anonymous. The survey, provided as a supplement, first asked five questions about HIV, which
included what it was, how it was transmitted, and how or if it could be effectively treated. The
next five questions asked respondents to rate on a zero-to-four scale different stigmatizing
statements based on how much they agreed with them. The survey also asked respondents their
gender, sexual orientation, age, and what department they were in at UT. All questions and
recruitment practices were approved by the Institutional Review Board. The survey was
discontinued after receiving 202 responses. Ninety percent of respondents were in the 18 to 24
age range, with the other ten percent as old as 64. The sample was disproportionately female at
67%. Eighty-two percent of respondents reported being straight, with 9% reporting as bisexual
and only 5% gay. The others reported being asexual, other, or preferred not to respond. Each
anonymous respondent was given a “stigma score” based on the combined numbers reported for
all stigma statements. Results were analyzed using a linear regression, t-tests, and nonparametric
Wilcox tests.
Results showed that only 27% of respondents correctly answered every knowledge-based
question. Ninety percent of respondents knew HIV was a virus, and 92% differentiated between
HIV and AIDS. About 78% were aware antiretrovirals were used to treat HIV, but only 69%

thought the 96% efficacy rate was true. Less than half correctly answered the question about
transmission correctly. When a regression was done between stigma score and correctly
answered questions (Figure 1), there was no significant trend. However, there were several
significant differences in stigma scores for specific questions when compared between answering
profiles for transmission methods. Because the question format allowed participants to check as
many options as they thought correct, there were many possible answers and thus only two
groups of respondents were considered: those who answered the question about transmission
completely correctly, with no fewer and no more answers than required, and those who thought
every transmission mode offered was correct. Not only were the overall stigma scores
significantly different between these two groups (Figure 3), there were also significant
differences in their agreement with statements about food handling by PLHIV (Figure 4),
proximity to PLHIV (Figure 5), and HIV being a punishment for bad behavior (Figure 6).
Despite these significant relationships, there was no difference in predicted self-shaming
between the two answering profiles (Figure 2). It should be noted that other questions (e.g.
treatment options, the difference between HIV and AIDS, efficacy of known treatments) did not
elicit the same differences in stigma.

Figure 1: Overall stigma score versus number of overall correct answers. Stigma scores were calculated by
adding degrees of agreement to each stigma statement together. There was no significant relationship
between overall knowledge and apparent stigma when an F-test was performed (p=0.1411).

n=117
p=0.0007

Figure 2: Stigma score compared between two groups with different awareness of how HIV can be
transmitted. The “all selected” group reported that all methods listed were possible ways of transmitting the
virus: contact with infected blood, unprotected sex, contact with “infected” saliva, sharing needles, and
mosquitoes. The “correct” group accurately reported all legitimate modes of transmission, no more and no
less. Both a t-test and Wilcox test showed a significant difference in overall stigma between these two groups
(p=0.0007).

n=117
p=0.21

Figure 3: Predicted internal stigma compared to understanding of transmission. Sample sizes are the same as
those listed in Figure 3. A t-test showed the difference to be insignificant.

n=117
p=0.0001

Figure 4: Fear of contracting HIV from someone living with HIV handling one’s food compared between two
groups with different levels of understanding of HIV transmission. Groups were the same as those stated in
Figure 2. The stigma level associated with food preparation by PLHIV for each group was obtained from the
stigma level reported on each survey, and then averaged. Sample sizes were the same as those used in Figure
2. Both a t-test and a Wilcox test showed there was significantly more fear of transmission within the group
selecting all transmission methods listed than within the group with only correct answers (p=0.0001).

n=117
p=0.0076

Figure 5: Fear of being in the same confined area with someone living with HIV compared between two
groups. The group selecting all modes of transmission listed showed significantly higher stigma scores than
those with a more accurate knowledge of HIV transmission in both a t-test and a Wilcox test (p=0.0076).
Sample sizes were the same as those in Figure 2.

n=117
p=0.0180

Figure 6: The average incidence of considering HIV a punishment for “bad behavior” between two groups.
The group with more correct answers was less likely to stigmatize PLHIV than those seeing all modes of
transmission listed as legitimate based on both a t-test and a Wilcox test (p=0.0180). Sample sizes were the
same as those on Figure 2. However, it should be noted that few respondents fully agreed with the statement
“HIV is a punishment for bad behavior.” Thus, this data should not be seen as confirming strong and
widespread stigma, but rather as confirming a difference in two groups’ tendencies to not completely reject
the statement.

Thus, the most pressing question surrounding these results is why one knowledge-based
question would be more important in predicting stigma than others, particularly over those about
the existence and efficacy of treatments. In addition, why would this trend not reflect in overall
stigma? That someone who thinks they can get HIV through more than unprotected sex or blood
exposure is fearful of contracting it in low risk situations makes sense. Even though it is based in
inaccuracy, believing HIV is spread more easily than it actually is could foreseeably lead to more
stigmatization, especially in the scope of food preparation or proximity. However, the same
should arguably be true for those people who think there are no available treatments for HIV, but
statistical analysis showed no significant difference between those who knew antiretrovirals are
the chosen treatment for HIV and those who thought there were no available treatments. It is
possible the survey design was flawed in that it asked about the efficacy of antiretrovirals after
asking about what treatments were used, but did not bar respondents from editing their previous
answers. However, if it is assumed the indifference would hold either way, it might be possible
that there is a larger fear associated with having to live with HIV than die of AIDS. If this is the
case, it speaks volumes about society’s perception of HIV and acknowledged stigma surrounding
HIV, as well as how little is actually known about the possibility of living a normal life with
HIV. That two of the five questions were about treatment, which seemed to have no bearing on
overall stigma, it is unsurprising that stigma could not be correlated with overall knowledge.
That the only question correlating with stigma was about transmission suggests that HIV stigma
is induced by fear of transmission, and that fear of getting HIV is borne out of an unclear
understanding of the virus. However, more work would have to be done to confirm this
relationship.

Though this survey did give some insight about stigma at UT Knoxville and the
relationship between knowledge and stigma, there were several limitations. The survey was kept
fairly short to encourage participation. A longer survey could have provided more room for
comparing knowledge and stigma. Even if the survey had been kept short, different questions
may have afforded more stigma than the ones used. More demographic questions could have
been added to establish better trends among minorities. Much of the existing literature about
stigma and HIV has evolved out of its association with homosexual men, so it would be
interesting to include a larger proportion in future study groups. Between this aspect and the fact
that over 60% of respondents were female, it could be beneficial to do more targeted distribution
to attain a more representative sample. This approach and any future endeavors might also
benefit from having a larger sample than the 202 in this survey. Finally, the location could also
affect the relationship between knowledge and stigma. According to a 2011 census, a higher
proportion of HIV diagnoses were in southern states, which may have implications for how
much is known or what might be stigmatized in the south (Reif 2014).

Living with HIV
Various studies have looked beyond the numbers to study the tangible, day-to-day effects
of living with HIV in a world that stigmatizes it. In a 2007 study conducted in Los Angeles, 48
HIV+ participants were put in groups and interviewed regarding their experiences with stigma.
The study categorized these experiences as follows: innocence discourse, fear of contagion,
disclosure, and negotiation of social contracts. “Innocence discourse” referred to the tendency for
others to ask about how someone with HIV contracted it, and use that information to assign

blame. Women described the difficulty in handling these questions, given how deeply personal it
can be. If they are not the victims of some unfortunate event such as a rape or blood transfusion,
they are presumed to be promiscuous or drug-users. Homosexual men experience a similar
stigma within the LGBT community, as shown by one man’s experience of overhearing other
gay men’s disgust with HIV+ men. Despite many people assuming PLHIV inherited HIV
through promiscuity or drug use, fear of contagion is another source of stigma, and what
separates HIV from other chronic diseases. Though HIV is transmitted through unprotected sex
or blood contact, people tend to harbor an irrational fear of contracting HIV through minimal
contact. These reports are in line with the UT-Knoxville survey results showing that people who
have an incorrect understanding of transmission have higher levels of stigma. Fears such as these
can limit how often PLHIV can enjoy platonic physical affection, sharing home-cooked meals,
or even having normal experiences with HIV-discordant friends. However, it should be noted
that successfully reestablishing these interactions with family members and friends can be
meaningful to someone coming to terms with his or her status, and ultimately help them resume
a less isolated existence (Sayles 2007).
Adding to possible isolation is the fear of disclosure common among PLHIV. Fear of
disclosing a positive serostatus arises from fear of being stigmatized, labelled, or being seen only
as someone with HIV. Such fear can creep into romantic relationships, career choices, and
general approach to being a part of society. Thus, PLHIV without social support have reported
avoiding intimacy to avoid disclosure, quitting jobs to avoid explaining inconsistent attendance
due to health issues, or avoiding enjoyable activities to avoid having to explain their situation to
others (Sayles 2007, Zhang 2016).

Although studies have shown having social support helps outlook in PLHIV, stigma still
affects those PLHIV who have maintained intimacy (Lee 2015, Rispel 2015). In the 2015 study
from Rispel et al, researchers found 50 HIV-discordant couples distributed across three countries
(Ukraine, Tanzania, and South Africa). Couples in the study gave testimonies of their
experiences with the public and their own family members. Couples in Africa were labelled as
being HIV-concordant and received pressure from their families to discontinue the relationship.
Often, family members were confused by the couple’s claims that the HIV- partner could
maintain his or her negative status, despite the existence and relative accessibility of HAART.
One couple in Tanzania even reported being called a “walking corpse.” Couples in Ukraine
experienced similar stigma, but also spoke more often of simply avoiding the subject of their
discordant status out of fear of their families’ reactions, or public treatment of their families
based on their proximity to HIV.
Despite the fact that PLHIV can be limited by the perceived stigma in their daily lives,
author Heather Boerner has captured today’s possibilities for PLHIV, specifically for those in
HIV-discordant relationships trying to have children. She emphasizes what can actually be
accomplished with the medications available today by telling the stories of two discordant
couples in which the husband was HIV+. Both couples struggled to find safe ways to fulfill their
dreams of having families. Though sperm washing for in vitro fertilization was a possibility
before the potential of antiretrovirals was discovered, there was a long-time ban on donating and
washing the sperm of HIV+ men, killing any hopes of safely creating a child of their own. Even
after the ban was repealed, the process remained expensive with little guarantee it would actually
work. However, a 2001 study in Uganda found that the transmission risk during unprotected sex
was directly related to viral load. The lower the treatment, the less likely transmission would

occur. In fact, the overall transmission risk per coital act was calculated being 0.1-0.2% (Gray
2001). Not long after the Uganda study, Dr. Myron Cohen began studying the effects of early
antiretroviral treatment on HIV-1 transmission. Though his findings were not published until
2011, his research eventually confirmed that treating HIV as early as possible led to extremely
low risks of transmission (Cohen 2011). Meanwhile, Boerner’s couples were scrambling for
ways to conceive children. Both couples decided to take what at the time seemed like a huge
risk—waiting for an ovulation cycle, testing both blood and semen for viral load, and carefully
planning Truvada treatments for the HIV- negative wife prior to having unprotected sex (Boerner
2014). Though the path was hardly easy for both couples, both were able to have healthy, HIVnegative children and keep HIV-negative partners virus-free. While these stories involved two
carefully controlled situations, they are still testament to what can be accomplished given the
right opportunities, and are probably the most compelling evidence for HIV becoming less of a
death sentence and more a chronic illness.

Accessibility
While the fact that PLHIV have more possibilities is a tremendous and wonderful step in
the right direction, the possibilities do not always become reality. The annual cost of
antiretroviral treatment is staggering. Pascual gives the figure 6.5 billion USD per year to treat a
mere 15 million PLHIV (Pascual 2014). Though programs like Medicaid and WHO guidelines to
increase access can help offset these costs, someone with HIV, particularly those in the United
States and Europe, can pay thousands of dollars per year for medications and healthcare (Koenig
2015). A major contributor to the ingoing expense of antiretrovirals is the patents companies are
allowed to hold for up to twenty years. During this time period, generics are not allowed to hit

the market, which keeps costs higher for long periods of time. A few loopholes have been added
to global policies in an attempt to soften the financial blow in less developed countries, such as
allowing other companies to begin work on generic versions of medication before the patents
expire and allowing companies in other countries to manufacture and sell a patent holder’s
product for a certain cut of the profit (Pascual 2014). These measures have been somewhat
effective in other countries, but those benefits have not extended to the United States, which
remains one of the highest paying countries for pharmaceuticals(Koenig 2015). High costs can
make it more difficult for people to obtain and adhere to their medications consistently, and the
consequences of improper adherence to HIV medications can be serious. If medications are not
taken as directed, it puts the patient at risk for not only increasing viral load above undetectable
levels, but also allows a larger reservoir to form and increases the likelihood of viral resistance
(Prevention 2016). Thus, if medications continue to be expensive with an ever increasing number
of PLHIV, there will be a higher number of individuals needing something more advanced and
even more expensive than the first line treatments available(Pascual 2014). All of this is to say
that, while pharmaceutical companies must make a profit just like any other company, HIV is not
a disease to be seen first and foremost as a business opportunity; rather, suppressing HIV needs
to truly be the primary goal for companies worldwide.
Another important aspect of preventing HIV transmission is detecting it as soon as
possible. The sooner a positive HIV status is discovered, the sooner medications can be
prescribed, and the less viral load someone will incur. Even if someone recently diagnosed with
HIV does not seek treatment right away for financial reasons or to evade the unpleasant side
effects of antiretrovirals, being aware enough to avoid overly risky situations is important with or
without medication. Therefore, access to affordable and discrete testing is pivotal. Options in the

United States include walk-in clinics, blood testing labs, and in-home oral HIV test kits. At forty
dollars, test kits are less expensive than going to a clinic or lab and are cheap compared to the
overall cost of being diagnosed with HIV. However, forty dollars becomes a steep price for low
income demographics, particularly adolescents. In a recent study focusing on low-income
adolescents in Chicago and San Francisco, teens were asked about their opinions on accessing
home testing kits. Even though they can be bought at drug stores, the forty dollar price tag was a
drawback, as well as the likelihood of being stigmatized or recognized while purchasing such a
kit. This may be especially problematic in smaller, less urban communities where faces are more
familiar and getting to a simple drug store may be more difficult. The investigators proposed a
mailing service or a vending system of sorts, in which more sensitive tests could be dispensed
without necessitating human interaction. Making these tests more universally available through
nonprofit organizations would also reduce the cost to about $11.00, just over a fourth of the
normal cost(Catania 2015). These same strategies may benefit women in the same situation as
those discussed in Turan’s study in Kenya. Their decision to get tested was heavily based on
their partner’s reaction to a positive HIV status. Perhaps offering a more discrete testing option
that could be performed without a clinic would alleviate those fears enough to increase
willingness to undergo an HIV test (Turan 2010).

Conclusions
Since the 1980s, HIV has become much more a part of the global vocabulary. Since then,
we have poured resources into studying the virus itself, how to keep it at bay, and how to destroy
the disease entirely. Even though we are far from actually curing HIV, we have made excellent
progress toward being able to coexist with it. By and large, it is access to care and perceived

stigma standing in the way of PLHIV living normal and happy lives, not so much what we have
or have not accomplished in the laboratory. The anonymous couples Heather Boerner sought out
are hopefully only the beginning of the successes for PLHIV. In the end, it seems PLHIV do not
need a cure to achieve the same basic needs as those without HIV. And yet, the stigma still
exists. Many studies, especially those from Rispel and Sayles, point toward
compartmentalization and avoidance as a way of coping with HIV. We as a society seem to do
the same, as common “solutions” to achieving greater testing and treatment success lies in
discretion and laying low (Catania 2015). Given the difficulties in completely eradicating viruses
overall, we need to be able to talk about HIV as an issue instead of sweeping it under a rug,
hoping it will go away. The facts about HIV, particularly those regarding transmission and how
to access treatment, need to be spread far and wide (Zhang 2016).
Though HIV has inspired a huge amount of global effort, it is not unique in its proclivity
for attracting stigma. Sexually transmitted infections (STIs) have seen a similar development of
stigma, and avoidance of diagnosis and treatment due to that stigma (Morris 2014). Perhaps the
largest separation between HIV and other STIs is the potential of an early death and little
progress on a true cure. Others can be treated with antibiotics, or at least are not liable to destroy
an immune system over time. And yet there is still significant stigma surrounding these lesser
diseases. Perhaps the label “sexually transmitted” has become a call for stigma, despite the
constant presence of sex and sexuality in our society. Perhaps this means that eradicating HIVrelated stigma is farther away than eradicating HIV itself.
As far as research goes, seeing people emulate work like the Uganda study or Dr.
Cohen’s would be a breath of fresh air, simply because they worked with what was available to
move mountains for HIV-discordant couples in the here and now instead of calling it impossible,

or chasing something that could be lightyears away. This is not to say progress is bad or
wasteful, but it is a reminder that progress can come in many forms. Taking steps such as these
to giving PLHIV the same lifestyle options as those without could go far in destigmatizing HIV.
By giving PLHIV an identity other than “PLHIV,” maybe we can start seeing them as more than
one decision, one life event, or one way to exist. The next step is making those scenarios outlined
by Boerner possible worldwide by providing cheaper medications faster, and continued
establishment of health clinics. That PLHIV can accomplish all the things they could without
HIV may not change stigma right away, or even in a lifetime, but actions can speak louder than
words.
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Supplement: HIV Awareness and Stigma Survey
1.
a.
b.
c.
d.
e.

What is HIV?
Cancer
A virus
A genetic disorder
Bacterial infection
A parasite

2.
Which of the following are ways HIV can be transmitted?
(Check all that apply)
Contact with HIV-positive blood
Unprotected sex
Contact with saliva from someone with HIV
Sharing needles
Mosquitoes
3.
a.
b.
c.
d.

How is HIV currently treated?
Antibiotics
Chemotherapy
Antiretrovirals
There are no known treatments for HIV

4.
True or False: Antiretrovirals are approximately 96% effective in preventing HIV
transmission when taken properly.
5.

True or False: HIV is the same thing as AIDS.

6.
On a scale of 0 (strongly disagree) to 4 (strongly agree), how much would you agree with
this statement?
If one of my family members contracted HIV, I would be ashamed.
0-strongly disagree
1-disagree
2-neutral
3-agree
4-strongly agree
7.
On a scale of 0 (strongly disagree) to 4 (strongly agree), how much would you agree with
this statement?
If I contracted HIV, I would be ashamed of myself.
0-strongly disagree
1-disagree

2-neutral
3-agree
4-strongly agree
8.
On a scale of 0 (strongly disagree) to 4 (strongly agree), how much would you agree with
this statement?
If someone living with HIV were to prepare my food, I would fear contracting HIV.
0-strongly disagree
1-disagree
2-neutral
3-agree
4-strongly agree
9.
On a scale of 0 (strongly disagree) to 4 (strongly agree), how much would you agree with
this statement?
If I were sitting in an enclosed space with someone with HIV, I would fear contracting HIV
myself.
0-strongly disagree
1-disagree
2-neutral
3-agree
4-strongly agree
10.
On a scale of 0 (strongly disagree) to 4 (strongly agree), how much would you agree with
this statement?
HIV is a punishment for bad behavior.
0-strongly disagree
1-disagree
2-neutral
3-agree
4-strongly agree
11.

How old are you?

12.

What is your gender?

13.

What is your sexual orientation?

14.

If you are student or faculty, what department are you in?

Role in Project
The Principal Investigator, Renee Adamec, conducted a survey of the University of TennesseeKnoxville’s students and faculty to try to correlate knowledge and stigma surrounding HIV. She
also reviewed scientific literature to inspire the survey, explain results, and suggest a new
perspective on HIV.
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